{
    "clinical_study": {
        "@rank": "70553", 
        "arm_group": [
            {
                "arm_group_label": "standard treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months)."
            }, 
            {
                "arm_group_label": "DEC 6 mg/kg + Alb 400 mg x 1", 
                "arm_group_type": "Experimental", 
                "description": "Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once"
            }, 
            {
                "arm_group_label": "DEC + ALB + IVM", 
                "arm_group_type": "Experimental", 
                "description": "Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 \u00b5g/kg administered once only at the beginning of the RCT (0 month)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine if a combination of 3 drugs used to treat the infection that cause\n      lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in\n      killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given\n      to treat this infection.  The three drugs used together are called albendazole (ALB),\n      ivermectin (IVM) and diethylcarbamazine (DEC).  The usual treatment in Papua New Guinea\n      (PNG) for lymphatic filariasis are DEC and ALB.  A combination of these 3 drugs has not been\n      previously used to treat LF."
        }, 
        "brief_title": "Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphatic Filariasis", 
        "condition_browse": {
            "mesh_term": [
                "Elephantiasis, Filarial", 
                "Elephantiasis", 
                "Filariasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will determine whether 1 or 2 annual treatments with the triple drug regimen of\n      DEC/Iver/Alb is equally or more effective than repeated annual treatments with DEC/Alb in\n      inducing sustained clearance of Mf in LF infected subjects previously determined to have\n      >100Mf/ml, indicative of a moderate to heavy infection.   Subjects will be treated and\n      monitored in several common areas near study subject residences.\n\n      There will be 3 treatment arms as follows:\n\n        1. The comparator  (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at\n           0, 12, and 24 months).\n\n        2. DEC 6 mg/kg + Alb 400 mg given once\n\n        3. DEC 6 mg/kg + Alb 400 mg + Iver 200 \u00b5g/kg administered once only at the beginning of\n           the RCT (0 month)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women 18-65 years\n\n          -  >100mf/ml in finger stick blood samples\n\n          -  Willing to give informed consent\n\n        Exclusion Criteria:\n\n          -  Prior treatment for LF within last 5 years\n\n          -  Pregnant (do pregnancy test)\n\n          -  Hemoglobin < 7 g/dl\n\n          -  permanent disability, serious medical illness that prevents or impedes study\n             participation and/or comprehension\n\n          -  AST/ALT and creatinine > 1.5 upper limit of normal.\n\n          -  Urine dipstick with glucose \u2265 2+ and/or protein \u2265 2+"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "225", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975441", 
            "org_study_id": "CWRU 3 vs 2 LF ELIM PNG"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "standard treatment", 
                    "DEC 6 mg/kg + Alb 400 mg x 1", 
                    "DEC + ALB + IVM"
                ], 
                "description": "Diethylcarbamazine 6mg/kg", 
                "intervention_name": "Diethylcarbamazine", 
                "intervention_type": "Drug", 
                "other_name": "DEC"
            }, 
            {
                "arm_group_label": [
                    "standard treatment", 
                    "DEC 6 mg/kg + Alb 400 mg x 1", 
                    "DEC + ALB + IVM"
                ], 
                "description": "Albendazole 400mg", 
                "intervention_name": "Albendazole", 
                "intervention_type": "Drug", 
                "other_name": "ALB, Albenda"
            }, 
            {
                "arm_group_label": "DEC + ALB + IVM", 
                "description": "Ivermectin 200 mcg/kg", 
                "intervention_name": "Ivermectin", 
                "intervention_type": "Drug", 
                "other_name": "IVM, Stromectol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albendazole", 
                "Diethylcarbamazine", 
                "Ivermectin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Diethycarbamazine", 
            "Albendazole", 
            "Ivermectin", 
            "Lymphatic filariasis"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "contact": {
                "email": "jsuamani@gmail.com", 
                "last_name": "James Suamani", 
                "phone": "+675 71066112"
            }, 
            "contact_backup": {
                "email": "manasseh.baea@gmail.com", 
                "last_name": "Manasseh Baea", 
                "phone": "+675 73332320"
            }, 
            "facility": {
                "address": {
                    "city": "Maprik", 
                    "country": "Papua New Guinea", 
                    "state": "East Sepik"
                }, 
                "name": "Papua New Guinean Institute for Medical Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Papua New Guinea"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa", 
        "overall_contact": {
            "email": "cxk21@case.edu", 
            "last_name": "Christopher L King, MD, PhD", 
            "phone": "4402476904"
        }, 
        "overall_contact_backup": {
            "last_name": "James W Kazura, MD"
        }, 
        "overall_official": {
            "affiliation": "Papua New Guinea Institution for Medical Research", 
            "last_name": "Peter Siba, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf)", 
            "safety_issue": "No", 
            "time_frame": "at 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975441"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Case Medical Center", 
            "investigator_full_name": "Christopher L. King, MD, PhD", 
            "investigator_title": "Professor/PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Hospital Case Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Case Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}